Also trades as: PTIXW (NASDAQ) · $vol 0M
PTIX NASDAQ
Protagenic Therapeutics, Inc.
1W: +32.6%
1M: -1.5%
3M: +37.7%
YTD: -12.2%
1Y: -94.1%
3Y: -97.9%
5Y: -99.5%
$0.62
-0.03 (-4.92%)
Weekly Expected Move ±38.3%
$0
$0
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.1M
52W Range0.25-6.2
Volume140
Avg Volume6,700
Beta0.47
Dividend—
Analyst Ratings
Company Info
CEOGaro H. Armen
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-27
Websiteprotagenic.com
149 Fifth Avenue
New York City, NY 10010
US
New York City, NY 10010
US
212 994 8200
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| EVANS BARRETT | 0 | — | 2025-05-15 | |
| EVANS BARRETT | 0 | — | 2025-05-15 | |
| EVANS BARRETT | 0 | — | 2025-05-15 | |
| EVANS BARRETT | 0 | — | 2025-05-15 | |
| EVANS BARRETT | 0 | — | 2025-05-15 |